Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast

 
 

Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021 and issued its financial outlook for 2022.

 
  • Fourth-quarter sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis, which excludes the impact of foreign exchange.
  •  
  • Fourth-quarter GAAP diluted EPS was $1.11 and adjusted diluted EPS, which excludes specified items, was $1.32 .
  •  
  • Full-year 2021 GAAP diluted EPS from continuing operations was $3.94 and adjusted diluted EPS from continuing operations was $5.21 , reflecting 42.7% growth versus the prior year. 1
  •  
  • Global COVID-19 testing-related sales were $2.3 billion in the fourth quarter and $7.7 billion for the full-year. Abbott has distributed more than 1.4 billion COVID-19 tests since the start of the pandemic.
  •  
  • Abbott issues full-year 2022 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.43 and full-year adjusted diluted EPS from continuing operations of at least $4.70 .
  •  
  • Full-year 2022 guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion , which Abbott expects to occur early in the year and will update on a quarterly basis.
  •  
  • Abbott's R&D pipeline continues to deliver a steady cadence of new products. Select 2021 highlights include U.S. Centers for Medicare & Medicaid Services expanded reimbursement for MitraClip ® , U.S. launches of Amplatzer ® Amulet ® , NeuroSphere Virtual Clinic, and Portico ® transcatheter aortic valve replacement (TAVR) system, along with the international launch of Navitor TAVR system.
  •  

"2021 was an outstanding year for Abbott," said Robert B. Ford , chairman and chief executive officer, Abbott. "We achieved more than 40 percent EPS growth, exceeding the baseline EPS guidance we set at the beginning of last year and, importantly, continued to advance our new product pipeline across the portfolio."

 

  FOURTH-QUARTER BUSINESS OVERVIEW
  Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.  

 

  Following are sales by business segment and commentary for the fourth quarter 2021:  

 
 
                                                                                                                                                                                                                                                                         
 

    Total Company    

 

  ($ in millions)  

 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 4Q20   

 
 
 
 

   Sales 4Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total *   

 
 
 

  4,855  

 
 
 

  6,613  

 
 
 

  11,468  

 
 
 

  15.6  

 
 
 

  1.7  

 
 
 

  7.2  

 
 
 

  15.6  

 
 
 

  2.7  

 
 
 

  7.7  

 
 

  Nutrition  

 
 
 

  928  

 
 
 

  1,114  

 
 
 

  2,042  

 
 
 

  10.4  

 
 
 

  1.7  

 
 
 

  5.5  

 
 
 

  10.4  

 
 
 

  2.4  

 
 
 

  5.9  

 
 

  Diagnostics  

 
 
 

  2,386  

 
 
 

  2,085  

 
 
 

  4,471  

 
 
 

  20.5  

 
 
 

  (11.8)  

 
 
 

  2.9  

 
 
 

  20.5  

 
 
 

  (11.1)  

 
 
 

  3.3  

 
 

  Established Pharmaceuticals  

 
 
 

  --  

 
 
 

  1,203  

 
 
 

  1,203  

 
 
 

  n/a  

 
 
 

  4.9  

 
 
 

  4.9  

 
 
 

  n/a  

 
 
 

  5.8  

 
 
 

  5.8  

 
 

  Medical Devices  

 
 
 

  1,538  

 
 
 

  2,211  

 
 
 

  3,749  

 
 
 

  12.3  

 
 
 

  17.1  

 
 
 

  15.1  

 
 
 

  12.3  

 
 
 

  18.6  

 
 
 

  15.9  

 
 
 

  * Total Q4 2021 Abbott sales from continuing operations include Other Sales of approximately $3 million.  

 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 12M20   

 
 
 
 

   Sales 12M21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total *   

 
 
 

  16,642  

 
 
 

  26,433  

 
 
 

  43,075  

 
 
 

  27.8  

 
 
 

  22.5  

 
 
 

  24.5  

 
 
 

  27.8  

 
 
 

  19.9  

 
 
 

  22.9  

 
 

  Nutrition  

 
 
 

  3,556  

 
 
 

  4,738  

 
 
 

  8,294  

 
 
 

  8.4  

 
 
 

  8.5  

 
 
 

  8.5  

 
 
 

  8.4  

 
 
 

  7.1  

 
 
 

  7.7  

 
 

  Diagnostics  

 
 
 

  7,129  

 
 
 

  8,515  

 
 
 

  15,644  

 
 
 

  49.3  

 
 
 

  41.2  

 
 
 

  44.8  

 
 
 

  49.3  

 
 
 

  37.4  

 
 
 

  42.7  

 
 

  Established Pharmaceuticals  

 
 
 

  --  

 
 
 

  4,718  

 
 
 

  4,718  

 
 
 

  n/a  

 
 
 

  9.6  

 
 
 

  9.6  

 
 
 

  n/a  

 
 
 

  10.4  

 
 
 

  10.4  

 
 

  Medical Devices  

 
 
 

  5,923  

 
 
 

  8,444  

 
 
 

  14,367  

 
 
 

  20.1  

 
 
 

  23.2  

 
 
 

  21.9  

 
 
 

  20.1  

 
 
 

  18.8  

 
 
 

  19.4  

 
 
 
 
      
 
 

  * Total 12M 2021 Abbott sales from continuing operations include Other Sales of approximately $52 million.  

 
 
 

  n/a = Not Applicable.  

 
 
 

  Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.  

 
 
 

Fourth-quarter 2021 worldwide sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis. Full-year 2021 worldwide sales increased 24.5 percent on a reported basis and 22.9 percent on an organic basis.

 

Worldwide sales, excluding COVID-19 testing-related sales, 2 increased 9.6 percent on a reported basis and 10.3 percent on an organic basis in the fourth quarter, and 15.2 percent on a reported basis and 13.7 percent on an organic basis in the full year 2021.

 

Compared to pre-pandemic sales in 2019, worldwide sales, excluding COVID-19 testing-related sales, 3 increased 10.0 percent on a reported basis and 10.8 percent on an organic basis in the fourth quarter.

 
 
                                                                                                                                                                                                         
 

    Nutrition
 
 
  ($ in millions)  

 
 
 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 4Q20   

 
 
 
 
 

   Sales 4Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 
 

  928  

 
 
 

  1,114  

 
 
 

  2,042  

 
 
 

  10.4  

 
 
 

  1.7  

 
 
 

  5.5  

 
 
 

  10.4  

 
 
 

  2.4  

 
 
 

  5.9  

 
 

  Pediatric  

 
 
 
 

  570  

 
 
 

  469  

 
 
 

  1,039  

 
 
 

  14.5  

 
 
 

  (8.0)  

 
 
 

  3.1  

 
 
 

  14.5  

 
 
 

  (8.1)  

 
 
 

  3.1  

 
 

  Adult  

 
 
 
 

  358  

 
 
 

  645  

 
 
 

  1,003  

 
 
 

  4.5  

 
 
 

  10.3  

 
 
 

  8.1  

 
 
 

  4.5  

 
 
 

  11.6  

 
 
 

  9.0  

 
 
 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 12M20   

 
 
 
 
 

   Sales 12M21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 
 

  3,556  

 
 
 

  4,738  

 
 
 

  8,294  

 
 
 

  8.4  

 
 
 

  8.5  

 
 
 

  8.5  

 
 
 

  8.4  

 
 
 

  7.1  

 
 
 

  7.7  

 
 

  Pediatric  

 
 
 
 

  2,192  

 
 
 

  2,106  

 
 
 

  4,298  

 
 
 

  10.3  

 
 
 

  (1.5)  

 
 
 

  4.2  

 
 
 

  10.3  

 
 
 

  (3.2)  

 
 
 

  3.3  

 
 

  Adult  

 
 
 
 

  1,364  

 
 
 

  2,632  

 
 
 

  3,996  

 
 
 

  5.6  

 
 
 

  18.1  

 
 
 

  13.5  

 
 
 

  5.6  

 
 
 

  17.0  

 
 
 

  12.8  

 
 
 

Worldwide Nutrition sales increased 5.5 percent on a reported basis and 5.9 percent on an organic basis in the fourth quarter.

 

In Adult Nutrition, strong performance of Ensure ® , Abbott's market-leading complete and balanced nutrition brand, and Glucerna ® , Abbott's market-leading diabetes nutrition brand, led to global sales growth of 8.1 percent on a reported basis and 9.0 percent on an organic basis.

 

Worldwide Pediatric Nutrition sales increased 3.1 percent on both a reported basis and organic basis. Strong performance of Abbott's market-leading oral hydration brand, Pedialyte ® , and continued share growth in infant nutrition led to U.S. Pediatric Nutrition growth of 14.5 percent. In International Pediatric Nutrition, sales were unfavorably impacted primarily by challenging market conditions in China .

 
 
                                                                                                                                                                                                                                                                                         
 

    Diagnostics    

 

  ($ in millions)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 4Q20   

 
 
 
 
 

   Sales 4Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 
 

  2,386  

 
 
 

  2,085  

 
 
 

  4,471  

 
 
 

  20.5  

 
 
 

  (11.8)  

 
 
 

  2.9  

 
 
 

  20.5  

 
 
 

  (11.1)  

 
 
 

  3.3  

 
 

  Core Laboratory  

 
 
 
 

  300  

 
 
 

  1,048  

 
 
 

  1,348  

 
 
 

  (8.0)  

 
 
 

  5.2  

 
 
 

  1.9  

 
 
 

  (8.0)  

 
 
 

  6.2  

 
 
 

  2.7  

 
 

  Molecular  

 
 
 
 

  135  

 
 
 

  210  

 
 
 

  345  

 
 
 

  (30.0)  

 
 
 

  (27.5)  

 
 
 

  (28.5)  

 
 
 

  (30.0)  

 
 
 

  (27.3)  

 
 
 

  (28.4)  

 
 

  Point of Care  

 
 
 
 

  95  

 
 
 

  40  

 
 
 

  135  

 
 
 

  5.3  

 
 
 

  3.7  

 
 
 

  4.8  

 
 
 

  5.3  

 
 
 

  3.9  

 
 
 

  4.9  

 
 

  Rapid Diagnostics  

 
 
 
 

  1,856  

 
 
 

  787  

 
 
 

  2,643  

 
 
 

  35.3  

 
 
 

  (24.2)  

 
 
 

  9.6  

 
 
 

  35.3  

 
 
 

  (23.8)  

 
 
 

  9.8  

 
 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 12M20   

 
 
 
 
 

   Sales 12M21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 
 

  7,129  

 
 
 

  8,515  

 
 
 

  15,644  

 
 
 

  49.3  

 
 
 

  41.2  

 
 
 

  44.8  

 
 
 

  49.3  

 
 
 

  37.4  

 
 
 

  42.7  

 
 

  Core Laboratory  

 
 
 
 

  1,145  

 
 
 

  3,983  

 
 
 

  5,128  

 
 
 

  (1.8)  

 
 
 

  20.4  

 
 
 

  14.6  

 
 
 

  (1.8)  

 
 
 

  17.4  

 
 
 

  12.4  

 
 

  Molecular  

 
 
 
 

  566  

 
 
 

  861  

 
 
 

  1,427  

 
 
 

  (8.9)  

 
 
 

  5.4  

 
 
 

  (0.8)  

 
 
 

  (8.9)  

 
 
 

  1.7  

 
 
 

  (2.9)  

 
 

  Point of Care  

 
 
 
 

  384  

 
 
 

  152  

 
 
 

  536  

 
 
 

  4.3  

 
 
 

  2.8  

 
 
 

  3.9  

 
 
 

  4.3  

 
 
 

  0.3  

 
 
 

  3.2  

 
 

  Rapid Diagnostics  

 
 
 
 

  5,034  

 
 
 

  3,519  

 
 
 

  8,553  

 
 
 

  92.2  

 
 
 

  100.2  

 
 
 

  95.4  

 
 
 

  92.2  

 
 
 

  95.0  

 
 
 

  93.3  

 
 
 

Worldwide Diagnostics sales increased 2.9 percent on a reported basis in the fourth quarter and increased 3.3 percent on an organic basis. Global COVID-19 testing-related sales were $2.3 billion in the fourth quarter, including combined sales of $2.1 billion from Abbott's BinaxNOW ® , Panbio ® and ID NOW ® rapid testing platforms.

 

Excluding COVID-19 testing-related sales, worldwide Diagnostics sales increased 8.2 percent on a reported basis in the fourth quarter and 8.7 percent on an organic basis. 4

 

In Molecular Diagnostics, fourth-quarter sales growth was negatively impacted by lower COVID-19 testing-related sales compared to the prior year. Excluding COVID-19 testing-related sales, worldwide Molecular Diagnostics sales increased 24.1 percent on a reported basis and 24.5 percent on an organic basis, including 34.6 percent in the U.S. and 20.7 percent internationally. 5

 

In Rapid Diagnostics, fourth-quarter international sales growth was negatively impacted by lower COVID-19 testing-related sales compared to the prior year. Excluding COVID-19 testing-related sales, international Rapid Diagnostics sales increased 9.7 percent on a reported basis and 10.3 percent on an organic basis. 6

 
 
                                                                                                                                                                                                          
 

    Established Pharmaceuticals    

 

  ($ in millions)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 4Q20   

 
 
 
 
 

   Sales 4Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 
 

  --  

 
 
 

  1,203  

 
 
 

  1,203  

 
 
 

  n/a  

 
 
 

  4.9  

 
 
 

  4.9  

 
 
 

  n/a  

 
 
 

  5.8  

 
 
 

  5.8  

 
 

  Key Emerging Markets  

 
 
 
 

  --  

 
 
 

  868  

 
 
 

  868  

 
 
 

  n/a  

 
 
 

  4.1  

 
 
 

  4.1  

 
 
 

  n/a  

 
 
 

  5.2  

 
 
 

  5.2  

 
 

  Other  

 
 
 
 

  --  

 
 
 

  335  

 
 
 

  335  

 
 
 

  n/a  

 
 
 

  6.8  

 
 
 

  6.8  

 
 
 

  n/a  

 
 
 

  7.5  

 
 
 

  7.5  

 
 
 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 12M20   

 
 
 
 
 

   Sales 12M21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 
 

  --  

 
 
 

  4,718  

 
 
 

  4,718  

 
 
 

  n/a  

 
 
 

  9.6  

 
 
 

  9.6  

 
 
 

  n/a  

 
 
 

  10.4  

 
 
 

  10.4  

 
 

  Key Emerging Markets  

 
 
 
 

  --  

 
 
 

  3,539  

 
 
 

  3,539  

 
 
 

  n/a  

 
 
 

  10.3  

 
 
 

  10.3  

 
 
 

  n/a  

 
 
 

  11.9  

 
 
 

  11.9  

 
 

  Other  

 
 
 
 

  --  

 
 
 

  1,179  

 
 
 

  1,179  

 
 
 

  n/a  

 
 
 

  7.8  

 
 
 

  7.8  

 
 
 

  n/a  

 
 
 

  6.0  

 
 
 

  6.0  

 
 
 

Established Pharmaceuticals sales increased 4.9 percent on a reported basis in the fourth quarter and increased 5.8 percent on an organic basis.

 

Key Emerging Markets include India , Brazil , Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 4.1 percent on a reported basis in the quarter and increased 5.2 percent on an organic basis. Organic sales growth was led by strong growth across several geographies, including India , Russia and China .

 

Other sales increased 6.8 percent on a reported basis in the quarter and increased 7.5 percent on an organic basis.

 
 
                                                                                                                                                                                                                                                                                                                                                                                         
 

    Medical Devices    

 

  ($ in millions)  

 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 4Q20   

 
 
 
 

   Sales 4Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 

  1,538  

 
 
 

  2,211  

 
 
 

  3,749  

 
 
 

  12.3  

 
 
 

  17.1  

 
 
 

  15.1  

 
 
 

  12.3  

 
 
 

  18.6  

 
 
 

  15.9  

 
 

  Rhythm Management  

 
 
 

  242  

 
 
 

  299  

 
 
 

  541  

 
 
 

  (2.7)  

 
 
 

  5.5  

 
 
 

  1.7  

 
 
 

  (2.7)  

 
 
 

  7.0  

 
 
 

  2.5  

 
 

  Electrophysiology  

 
 
 

  198  

 
 
 

  306  

 
 
 

  504  

 
 
 

  7.2  

 
 
 

  15.4  

 
 
 

  12.0  

 
 
 

  7.2  

 
 
 

  17.8  

 
 
 

  13.5  

 
 

  Heart Failure  

 
 
 

  171  

 
 
 

  68  

 
 
 

  239  

 
 
 

  25.4  

 
 
 

  30.8  

 
 
 

  26.9  

 
 
 

  25.4  

 
 
 

  33.2  

 
 
 

  27.6  

 
 

  Vascular  

 
 
 

  231  

 
 
 

  447  

 
 
 

  678  

 
 
 

  3.0  

 
 
 

  18.0  

 
 
 

  12.4  

 
 
 

  3.0  

 
 
 

  19.2  

 
 
 

  13.2  

 
 

  Structural Heart  

 
 
 

  193  

 
 
 

  226  

 
 
 

  419  

 
 
 

  25.4  

 
 
 

  13.6  

 
 
 

  18.7  

 
 
 

  25.4  

 
 
 

  15.7  

 
 
 

  19.9  

 
 

  Neuromodulation  

 
 
 

  156  

 
 
 

  41  

 
 
 

  197  

 
 
 

  (9.0)  

 
 
 

  (2.2)  

 
 
 

  (7.7)  

 
 
 

  (9.0)  

 
 
 

  (1.1)  

 
 
 

  (7.5)  

 
 

  Diabetes Care  

 
 
 

  347  

 
 
 

  824  

 
 
 

  1,171  

 
 
 

  38.8  

 
 
 

  23.5  

 
 
 

  27.6  

 
 
 

  38.8  

 
 
 

  24.3  

 
 
 

  28.3  

 
 
 
 
 
 
 
 
 
 
 

   % Change vs. 12M20   

 
 
 
 

   Sales 12M21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 

  5,923  

 
 
 

  8,444  

 
 
 

  14,367  

 
 
 

  20.1  

 
 
 

  23.2  

 
 
 

  21.9  

 
 
 

  20.1  

 
 
 

  18.8  

 
 
 

  19.4  

 
 

  Rhythm Management  

 
 
 

  1,018  

 
 
 

  1,180  

 
 
 

  2,198  

 
 
 

  12.7  

 
 
 

  16.8  

 
 
 

  14.8  

 
 
 

  12.7  

 
 
 

  12.7  

 
 
 

  12.7  

 
 

  Electrophysiology  

 
 
 

  778  

 
 
 

  1,129  

 
 
 

  1,907  

 
 
 

  17.7  

 
 
 

  23.1  

 
 
 

  20.8  

 
 
 

  17.7  

 
 
 

  20.0  

 
 
 

  19.1  

 
 

  Heart Failure  

 
 
 

  654  

 
 
 

  235  

 
 
 

  889  

 
 
 

  19.5  

 
 
 

  22.0  

 
 
 

  20.1  

 
 
 

  19.5  

 
 
 

  18.1  

 
 
 

  19.1  

 
 

  Vascular  

 
 
 

  915  

 
 
 

  1,739  

 
 
 

  2,654  

 
 
 

  7.4  

 
 
 

  17.0  

 
 
 

  13.5  

 
 
 

  7.4  

 
 
 

  13.2  

 
 
 

  11.1  

 
 

  Structural Heart  

 
 
 

  730  

 
 
 

  880  

 
 
 

  1,610  

 
 
 

  35.1  

 
 
 

  24.5  

 
 
 

  29.1  

 
 
 

  35.1  

 
 
 

  20.4  

 
 
 

  26.8  

 
 

  Neuromodulation  

 
 
 

  616  

 
 
 

  165  

 
 
 

  781  

 
 
 

  9.3  

 
 
 

  19.2  

 
 
 

  11.3  

 
 
 

  9.3  

 
 
 

  14.3  

 
 
 

  10.3  

 
 

  Diabetes Care  

 
 
 

  1,212  

 
 
 

  3,116  

 
 
 

  4,328  

 
 
 

  40.3  

 
 
 

  29.6  

 
 
 

  32.5  

 
 
 

  40.3  

 
 
 

  24.3  

 
 
 

  28.5  

 
 
 

Worldwide Medical Devices sales increased 15.1 percent on a reported basis in the fourth quarter and increased 15.9 percent on an organic basis. Strong growth in the quarter was driven by continued recovery from the COVID-19 pandemic and strong growth in Diabetes Care.

 

Compared to pre-pandemic sales in 2019, Medical Devices sales increased 17.0 percent on a reported basis and 15.8 percent on an organic basis in the fourth quarter, led by double-digit growth in Heart Failure, Structural Heart and Diabetes Care. 7

 

In Diabetes Care, FreeStyle Libre ® sales were $1.0 billion in the quarter, which represents sales growth of 35.4 percent on a reported basis and 36.0 percent on an organic basis.

 

Abbott continued to strengthen its Medical Devices portfolio with several pipeline advancements in 2021, including:

 
  • U.S. Centers for Medicare & Medicaid Services expanded reimbursement coverage for Abbott's revolutionary MitraClip device.
  •  
  • U.S. launch of NeuroSphere Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians and receive new treatment settings remotely as needed.
  •  
  • U.S. FDA approval of Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation who are at risk of ischemic stroke.
  •  
  • U.S. FDA approval of Portico with FlexNav ®   transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high risk for open-heart surgery.
  •  
  • CE Mark for Navitor, Abbott's latest-generation TAVR system.
  •  

  ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43 . Abbott forecasts specified items for the full-year 2022 of $1.27 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $4.70 for the full-year 2022.

 

Abbott projects first-quarter 2022 diluted earnings per share from continuing operations under GAAP of at least $1.20 . Abbott forecasts specified items for the first-quarter 2022 of $0.30 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $1.50 for the first quarter.

 

  ABBOTT DECLARES 392 ND CONSECUTIVE QUARTERLY DIVIDEND
On Dec. 10, 2021 , the board of directors of Abbott declared the company's quarterly dividend of $0.47 per share. Abbott's cash dividend is payable Feb. 15, 2022 to shareholders of record at the close of business on Jan. 14, 2022 .

 

Abbott has increased its dividend payout for 50 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

 

  About Abbott:  
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

 

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

 

Abbott will live-webcast its fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later that day.  
 

 

   Private Securities Litigation Reform Act of 1995 —
  A Caution Concerning Forward-Looking Statements  

 

  Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020 , and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.  

 
 
              
 

   1  

 
 

  Full-year 2021 diluted EPS from continuing operations on a GAAP basis reflects 58.2 percent growth.  

 
 

   2  

 
 

  In the fourth quarter of 2020, total worldwide sales were $10.701 billion, which included COVID-19 testing-related sales of $2.35 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion. Full-year 2020 worldwide sales were $34.608 billion, which included COVID-19 testing-related sales of $3.878 billion. Full-year 2021 COVID-19 testing-related sales were $7.679 billion.  

 
 

   3  

 
 

  In the fourth quarter of 2019, total worldwide sales were $8.314 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion. Full-year 2019 worldwide sales were $31.904 billion. Full-year 2021 COVID-19 testing-related sales were $7.679 billion.  

 
 

   4  

 
 

  In the fourth quarter of 2020, worldwide Diagnostic sales were $4.345 billion, which included total COVID-19 testing-related sales of $2.35 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion. Full-year 2020 worldwide Diagnostic sales were $10.805 billion, which included COVID-19 testing-related sales of $3.878 billion in Diagnostics. Full-year 2021 COVID-19 testing-related sales were $7.679 billion.  

 
 

   5  

 
 

  In the fourth quarter of 2020, worldwide Molecular sales were $482 million, which included $192 million of U.S. sales and $290 million of international sales. U.S. and international Molecular COVID-19 testing-related sales in the fourth quarter of 2020 were $158 million and $201 million, respectively. In the fourth quarter of 2021, U.S. and international Molecular COVID-19 testing-related sales were $89 million and $103 million, respectively.  

 
 

   6  

 
 

  In the fourth quarter of 2020, international Rapid Diagnostics sales were $1.039 billion, which included COVID-19 testing related sales of $847 million. In the fourth quarter of 2021, international Rapid Diagnostics COVID-19 testing related sales were $577 million.  

 
 

   7  

 
 

  In the fourth quarter of 2019, Medical Devices sales were $3.204 billion.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                          
 

  Abbott Laboratories and Subsidiaries  

 

  Condensed Consolidated Statement of Earnings  

 

  Fourth Quarter Ended December 31, 2021 and 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

   4Q21   

 
 
 

   4Q20   

 
 
 

   % Change   

 
 
 

  Net Sales  

 
 
 

  $11,468  

 
 
 

  $10,701  

 
 
 

  7.2  

 
 
 
 
 
 
 
 
 
 
 

  Cost of products sold, excluding amortization expense  

 
 
 

  4,766  

 
 
 

  4,493  

 
 
 

  6.1  

 
 
 

  Amortization of intangible assets  

 
 
 

  514  

 
 
 

  508  

 
 
 

  1.3  

 
 
 

  Research and development  

 
 
 

  762  

 
 
 

  698  

 
 
 

  9.1  

 
 
 

  Selling, general, and administrative  

 
 
 

  3,048  

 
 
 

  2,570  

 
 
 

  18.6  

 
 
 

  Total Operating Cost and Expenses  

 
 
 

  9,090  

 
 
 

  8,269  

 
 
 

  9.9  

 
 
 
 
 
 
 
 
 
 
 

  Operating Earnings  

 
 
 

  2,378  

 
 
 

  2,432  

 
 
 

  (2.2)  

 
 
 
 
 
 
 
 
 
 
 

  Interest expense, net  

 
 
 

  120  

 
 
 

  127  

 
 
 

  (5.7)  

 
 
 

  Net foreign exchange (gain) loss  

 
 
 

  (6)  

 
 
 

  (5)  

 
 
 

  22.8  

 
 
 

  Other (income) expense, net  

 
 
 

  (63)  

 
 
 

  (78)  

 
 
 

  (19.3)  

 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  2,327  

 
 
 

  2,388  

 
 
 

  (2.5)  

 
 
 
 
 
 
 
 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

  338  

 
 
 

  230  

 
 
 

  47.2  

 
 

  1)  

 
 

  Earnings from Continuing Operations  

 
 
 

  1,989  

 
 
 

  2,158  

 
 
 

  (7.8)  

 
 
 
 
 
 
 
 
 
 
 

  Earnings from Discontinued Operations, net of taxes  

 
 
 

  --  

 
 
 

  4  

 
 
 

  n/m  

 
 
 
 
 
 
 
 
 
 
 

  Net Earnings  

 
 
 

  $1,989  

 
 
 

  $2,162  

 
 
 

  (8.0)  

 
 
 
 
 
 
 
 
 
 
 

  Earnings from Continuing Operations, excluding  

 
 
 
 
 
 
 
 
 

  Specified Items, as described below  

 
 
 

  $2,366  

 
 
 

  $2,612  

 
 
 

  (9.4)  

 
 

  2)  

 
 
 
 
 
 
 
 
 
 

  Diluted Earnings per Common Share from:  

 
 
 
 
 
 
 
 
 

  Continuing Operations  

 
 
 

  $1.11  

 
 
 

  $1.20  

 
 
 

  (7.5)  

 
 
 

  Discontinued Operations  

 
 
 

  --  

 
 
 

  --  

 
 
 

  n/m  

 
 
 

  Total  

 
 
 

  $1.11  

 
 
 

  $1.20  

 
 
 

  (7.5)  

 
 
 
 
 
 
 
 
 
 
 

  Diluted Earnings per Common Share from Continuing  

 
 
 
 
 
 
 
 
 

  Operations, excluding Specified Items, as described below  

 
 
 

  $1.32  

 
 
 

  $1.45  

 
 
 

  (9.0)  

 
 

  2)  

 
 
 
 
 
 
 
 
 
 

  Average Number of Common Shares Outstanding  

 
 
 
 
 
 
 
 
 

  Plus Dilutive Common Stock Options  

 
 
 

  1,782  

 
 
 

  1,789  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 

  NOTES:  

 
 

  See tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations" for an explanation of certain non-GAAP financial information.  

 
 

  n/m = Percent change is not meaningful.  

 
 

  See footnotes on the following table.  

 
 
 
 
                
 
 
 

  1)  

 
 

  2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.  

 
 
 
 
 

  2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $10 million in excess tax benefits associated with share-based compensation.  

 
 
 
 

  2)  

 
 

  2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $377 million, or $0.21 per share, for intangible amortization and other expenses primarily associated with restructuring actions and acquisitions, partially offset by a change in estimate to the restructuring actions recognized in the second quarter related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.  

 
 
 
 
 

  2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $454 million, or $0.25 per share, for intangible amortization and impairment expenses and other net expenses primarily associated with acquisitions and restructuring actions.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                          
 

  Abbott Laboratories and Subsidiaries  

 

  Condensed Consolidated Statement of Earnings  

 

  Year Ended December 31, 2021 and 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

   12M21   

 
 
 

   12M20   

 
 
 

   % Change   

 
 
 

  Net Sales  

 
 
 

  $43,075  

 
 
 

  $34,608  

 
 
 

  24.5  

 
 
 
 
 
 
 
 
 
 
 

  Cost of products sold, excluding amortization expense  

 
 
 

  18,537  

 
 
 

  15,003  

 
 
 

  23.6  

 
 
 

  Amortization of intangible assets  

 
 
 

  2,047  

 
 
 

  2,132  

 
 
 

  (4.0)  

 
 
 

  Research and development  

 
 
 

  2,742  

 
 
 

  2,420  

 
 
 

  13.3  

 
 
 

  Selling, general, and administrative  

 
 
 

  11,324  

 
 
 

  9,696  

 
 
 

  16.8  

 
 
 

  Total Operating Cost and Expenses  

 
 
 

  34,650  

 
 
 

  29,251  

 
 
 

  18.5  

 
 
 
 
 
 
 
 
 
 
 

  Operating Earnings  

 
 
 

  8,425  

 
 
 

  5,357  

 
 
 

  57.3  

 
 
 
 
 
 
 
 
 
 
 

  Interest expense, net  

 
 
 

  490  

 
 
 

  500  

 
 
 

  (2.0)  

 
 
 

  Net foreign exchange (gain) loss  

 
 
 

  1  

 
 
 

  (8)  

 
 
 

  n/m  

 
 
 

  Other (income) expense, net  

 
 
 

  (277)  

 
 
 

  (103)  

 
 
 

  169.7  

 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  8,211  

 
 
 

  4,968  

 
 
 

  65.3  

 
 
 
 
 
 
 
 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

  1,140  

 
 
 

  497  

 
 
 

  129.4  

 
 

  1)  

 
 

  Earnings from Continuing Operations  

 
 
 

  7,071  

 
 
 

  4,471  

 
 
 

  58.2  

 
 
 
 
 
 
 
 
 
 
 

  Earnings from Discontinued Operations, net of taxes  

 
 
 

  --  

 
 
 

  24  

 
 
 

  n/m  

 
 
 
 
 
 
 
 
 
 
 

  Net Earnings  

 
 
 

  $7,071  

 
 
 

  $4,495  

 
 
 

  57.3  

 
 
 
 
 
 
 
 
 
 
 

  Earnings from Continuing Operations, excluding  

 
 
 
 
 
 
 
 
 

  Specified Items, as described below  

 
 
 

  $9,367  

 
 
 

  $6,552  

 
 
 

  43.0  

 
 

  2)  

 
 
 
 
 
 
 
 
 
 

  Diluted Earnings per Common Share from:  

 
 
 
 
 
 
 
 
 

  Continuing Operations  

 
 
 

  $3.94  

 
 
 

  $2.49  

 
 
 

  58.2  

 
 
 

  Discontinued Operations  

 
 
 

  --  

 
 
 

  0.01  

 
 
 

  n/m  

 
 
 

  Total  

 
 
 

  $3.94  

 
 
 

  $2.50  

 
 
 

  57.6  

 
 
 
 
 
 
 
 
 
 
 

  Diluted Earnings per Common Share from Continuing  

 
 
 
 
 
 
 
 
 

  Operations, excluding Specified Items, as described below  

 
 
 

  $5.21  

 
 
 

  $3.65  

 
 
 

  42.7  

 
 

  2)  

 
 
 
 
 
 
 
 
 
 

  Average Number of Common Shares Outstanding  

 
 
 
 
 
 
 
 
 

  Plus Dilutive Common Stock Options  

 
 
 

  1,789  

 
 
 

  1,786  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 

  See tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations" for an explanation of certain non-GAAP financial information.  

 
 

  n/m = Percent change is not meaningful.  

 
 

  See footnotes on the following table.  

 
 
 
 
                
 
 
 

  1)  

 
 

  2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.  

 
 
 
 
 

  2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $170 million of tax benefits related to the impairment of certain assets, $140 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $100 million in excess tax benefits associated with share-based compensation.  

 
 
 
 

  2)  

 
 

  2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.296 billion, or $1.27 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.  

 
 
 
 
 

  2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.081 billion, or $1.16 per share, for intangible amortization expense, impairment charges and other net expense primarily associated with acquisitions, restructuring actions and income from a litigation settlement.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                        
 

  Abbott Laboratories and Subsidiaries  

 

  Non-GAAP Reconciliation of Financial Information From Continuing Operations  

 

  Fourth Quarter Ended December 31, 2021 and 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 

   4Q21   

 
 
 
 

   As
Reported (GAAP)
 
 

 
 
 

   Specified Items   

 
 
 

   As
Adjusted
 
 

 
 
 

   % to Sales   

 
 
 
 
 
 
 
 
 
 
 

  Intangible Amortization  

 
 
 

   $            514   

 
 
 

  $     (514)  

 
 
 

   $          --   

 
 
 
 

  Gross Margin  

 
 
 

   6,188   

 
 
 

  434  

 
 
 

   6,622   

 
 
 

  57.7%  

 
 

  R&D  

 
 
 

   762   

 
 
 

  (39)  

 
 
 

   723   

 
 
 

  6.3%  

 
 

  SG&A  

 
 
 

   3,048   

 
 
 

  (43)  

 
 
 

   3,005   

 
 
 

  26.2%  

 
 

  Other (income) expense, net  

 
 
 

   (63)   

 
 
 

  (5)  

 
 
 

   (68)   

 
 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

   2,327   

 
 
 

  521  

 
 
 

   2,848   

 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

   338   

 
 
 

  144  

 
 
 

   482   

 
 
 
 

  Earnings from Continuing Operations  

 
 
 

   1,989   

 
 
 

  377  

 
 
 

   2,366   

 
 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 

   $1.11   

 
 
 

  $0.21  

 
 
 

   $1.32   

 
 
 
 
 

  Specified items reflect intangible amortization expense of $514 million and other net expenses of $7 million that includes costs associated with acquisitions and other expenses, partially offset by a change in estimate to the restructuring actions recognized in the second quarter. See titled "Details of Specified Items" for additional details regarding specified items.  

 
 
 
 
 

   4Q20   

 
 
 
 

   As
Reported (GAAP)
 
 

 
 
 

   Specified Items   

 
 
 

   As
Adjusted
 
 

 
 
 

   % to Sales   

 
 
 
 
 
 
 
 
 
 
 

  Intangible Amortization  

 
 
 

   $            508   

 
 
 

  $      (508)  

 
 
 

   $          --   

 
 
 
 

  Gross Margin  

 
 
 

   5,700   

 
 
 

  557  

 
 
 

   6,257   

 
 
 

  58.5%  

 
 

  R&D  

 
 
 

   698   

 
 
 

  (61)  

 
 
 

   637   

 
 
 

  6.0%  

 
 

  SG&A  

 
 
 

   2,570   

 
 
 

  (56)  

 
 
 

   2,514   

 
 
 

  23.5%  

 
 

  Other (income) expense, net  

 
 
 

   (78)   

 
 
 

  23  

 
 
 

   (55)   

 
 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

   2,388   

 
 
 

  651  

 
 
 

   3,039   

 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

   230   

 
 
 

  197  

 
 
 

   427   

 
 
 
 

  Earnings from Continuing Operations  

 
 
 

   2,158   

 
 
 

  454  

 
 
 

   2,612   

 
 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 

   $1.20   

 
 
 

  $0.25  

 
 
 

   $1.45   

 
 
 
 
 

  Specified items reflect intangible amortization expense of $508 million and other net expenses of $143 million, primarily associated with acquisitions, restructuring actions and other expenses. See tables titled "Details of Specified Items" for additional details regarding specified items.  

 
 
 
 

  Abbott Laboratories and Subsidiaries  

 

  Non-GAAP Reconciliation of Financial Information From Continuing Operations  

 

  Year Ended December 31, 2021 and 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

   12M21   

 
 
 
 

   As
Reported (GAAP)
 
 

 
 
 

   Specified Items   

 
 
 

   As
Adjusted
 
 

 
 
 

   % to Sales   

 
 
 
 
 
 
 
 
 
 
 

  Intangible Amortization  

 
 
 

   $         2,047   

 
 
 

  $  (2,047)  

 
 
 

   $          --   

 
 
 
 

  Gross Margin  

 
 
 

   22,491   

 
 
 

  2,476  

 
 
 

   24,967   

 
 
 

  58.0%  

 
 

  R&D  

 
 
 

   2,742   

 
 
 

  (106)  

 
 
 

   2,636   

 
 
 

  6.1%  

 
 

  SG&A  

 
 
 

   11,324   

 
 
 

  (317)  

 
 
 

   11,007   

 
 
 

  25.6%  

 
 

  Other (income) expense, net  

 
 
 

   (277)   

 
 
 

  25  

 
 
 

   (252)   

 
 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

   8,211   

 
 
 

  2,874  

 
 
 

   11,085   

 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

   1,140   

 
 
 

  578  

 
 
 

   1,718   

 
 
 
 

  Earnings from Continuing Operations  

 
 
 

   7,071   

 
 
 

  2,296  

 
 
 

   9,367   

 
 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 

   $3.94   

 
 
 

  $1.27  

 
 
 

   $5.21   

 
 
 
 
 

  Specified items reflect intangible amortization expense of $2.047 billion and other net expenses of $827 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See tables titled "Details of Specified Items" for additional details regarding specified items.  

 
 
 
 
 

   12M20   

 
 
 
 

   As
Reported (GAAP)
 
 

 
 
 

   Specified Items   

 
 
 

   As
Adjusted
 
 

 
 
 

   % to Sales   

 
 
 
 
 
 
 
 
 
 
 

  Intangible Amortization  

 
 
 

   $          2,132   

 
 
 

  $   (2,132)  

 
 
 

   $          --   

 
 
 
 

  Gross Margin  

 
 
 

   17,473   

 
 
 

  2,452  

 
 
 

   19,925   

 
 
 

  57.6%  

 
 

  R&D  

 
 
 

   2,420   

 
 
 

  (125)  

 
 
 

   2,295   

 
 
 

  6.6%  

 
 

  SG&A  

 
 
 

   9,696   

 
 
 

  (75)  

 
 
 

   9,621   

 
 
 

  27.8%  

 
 

  Other (income) expense, net  

 
 
 

   (103)   

 
 
 

  (88)  

 
 
 

   (191)   

 
 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

   4,968   

 
 
 

  2,740  

 
 
 

   7,708   

 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

   497   

 
 
 

  659  

 
 
 

   1,156   

 
 
 
 

  Earnings from Continuing Operations  

 
 
 

   4,471   

 
 
 

  2,081  

 
 
 

   6,552   

 
 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 

   $2.49   

 
 
 

  $1.16  

 
 
 

   $3.65   

 
 
 
 
 

  Specified items reflect intangible amortization expense of $2.132 billion and other net expenses of $608 million, primarily associated with acquisitions, restructuring actions, asset impairments, and other expenses and litigation settlement income. See tables titled "Details of Specified Items" for additional details regarding specified items.  

 
 
 
 
 
  
 

  A reconciliation of the fourth-quarter tax rates for continuing operations for 2021 and 2020 is shown below:  

 
 
 
 
 
                                                                                              
 
 
 
 

   4Q21   

 
 
 
 

  ($ in millions)  

 
 
 

   Pre-Tax Income   

 
 
 

   Taxes on Earnings   

 
 
 

   Tax
Rate
 
 

 
 
 
 

   As reported (GAAP)   

 
 
 

   $2,327   

 
 
 

   $         338   

 
 
 

   14.5%   

 
 

  1)  

 
 
 

  Specified items  

 
 
 

  521  

 
 
 

  144  

 
 
 
 
 
 

   Excluding specified items   

 
 
 

   $2,848   

 
 
 

   $482   

 
 
 

   16.9%   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   4Q20   

 
 
 
 

  ($ in millions)  

 
 
 

   Pre-Tax Income   

 
 
 

   Taxes on Earnings   

 
 
 

   Tax
Rate
 
 

 
 
 
 

   As reported (GAAP)   

 
 
 

   $2,388   

 
 
 

   $230   

 
 
 

   9.6%   

 
 

  2)  

 
 
 

  Specified items  

 
 
 

  651  

 
 
 

  197  

 
 
 
 
 
 

   Excluding specified items   

 
 
 

   $3,039   

 
 
 

   $427   

 
 
 

   14.1%   

 
 
 
 
 
 
        
 
 
 

  1)  

 
 

  2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.  

 
 
 
 

  2)  

 
 

  2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $10 million in excess tax benefits associated with share-based compensation.  

 
 
 
 
   
 
 

  A reconciliation of the year-to-date tax rates for continuing operations for 2021 and 2020 is shown below:  

 
 
 
 
 
                                                                                              
 
 
 
 

   12M21   

 
 
 
 

  ($ in millions)  

 
 
 

   Pre-Tax Income   

 
 
 

   Taxes on Earnings   

 
 
 

   Tax
Rate
 
 

 
 
 
 

   As reported (GAAP)   

 
 
 

   $8,211   

 
 
 

   $      1,140   

 
 
 

   13.9%   

 
 

  3)  

 
 
 

  Specified items  

 
 
 

  2,874  

 
 
 

  578  

 
 
 
 
 
 

   Excluding specified items   

 
 
 

   $11,085   

 
 
 

   $1,718   

 
 
 

   15.5%   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   12M20   

 
 
 
 

  ($ in millions)  

 
 
 

   Pre-Tax Income   

 
 
 

   Taxes on Earnings   

 
 
 

   Tax
Rate
 
 

 
 
 
 

   As reported (GAAP)   

 
 
 

   $4,968   

 
 
 

   $497   

 
 
 

   10.0%   

 
 

  4)  

 
 
 

  Specified items  

 
 
 

  2,740  

 
 
 

  659  

 
 
 
 
 
 

   Excluding specified items   

 
 
 

   $7,708   

 
 
 

   $1,156   

 
 
 

   15.0%   

 
 
 
 
 
 
        
 
 
 

  3)  

 
 

  2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.  

 
 
 
 

  4)  

 
 

  2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $170 million of tax benefits related to the impairment of certain assets, approximately $140 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $100 million in excess tax benefits associated with share-based compensation.  

 
 
 

 

 
 
                                                                                                                          
 

  Abbott Laboratories and Subsidiaries  

 

  Details of Specified Items  

 

  Fourth Quarter Ended December 31, 2021  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

  Acquisition or Divestiture-related (a)  

 
 
 

  Restructuring and Cost Reduction Initiatives (b)  

 
 
 

  Intangible Amortization  

 
 
 

  Other (c)  

 
 
 

  Total Specifieds  

 
 
 

  Gross Margin  

 
 
 

  $               26  

 
 
 

  $           (110)  

 
 
 

  $           514  

 
 
 

  $          4  

 
 
 

  $       434  

 
 
 

  R&D  

 
 
 

  (6)  

 
 
 

  (8)  

 
 
 

  --  

 
 
 

  (25)  

 
 
 

  (39)  

 
 
 

  SG&A  

 
 
 

  (12)  

 
 
 

  (23)  

 
 
 

  --  

 
 
 

  (8)  

 
 
 

  (43)  

 
 
 

  Other (income) expense, net  

 
 
 

  (2)  

 
 
 

  --  

 
 
 

  --  

 
 
 

  (3)  

 
 
 

  (5)  

 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  $               46  

 
 
 

  $             (79)  

 
 
 

  $           514  

 
 
 

  $        40  

 
 
 

  521  

 
 
 

  Tax expense on Earnings from Continuing Operations (d)  

 
 
 
 
 
 
 
 
 
 
 

  144  

 
 
 

  Earnings from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $       377  

 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $      0.21  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 

  The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations."  

 
 
 
 

  a)  

 
 

  Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.  

 
 

  b)  

 
 

  Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes a credit associated with a change in estimate to the charges taken in the second quarter for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.  

 
 

  c)  

 
 

  Other includes incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.  

 
 

  d)  

 
 

  Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.  

 
 
 

 

 
 
                                                                                                                          
 

  Abbott Laboratories and Subsidiaries  

 

  Details of Specified Items  

 

  Fourth Quarter Ended December 31, 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

  Acquisition or Divestiture-related (a)  

 
 
 

  Restructuring and Cost Reduction Initiatives (b)  

 
 
 

  Intangible Amortization  

 
 
 

  Other (c)  

 
 
 

  Total Specifieds  

 
 
 

  Gross Margin  

 
 
 

  $               23  

 
 
 

  $              23  

 
 
 

  $           508  

 
 
 

  $          3  

 
 
 

  $       557  

 
 
 

  R&D  

 
 
 

  (2)  

 
 
 

  6  

 
 
 

  --  

 
 
 

  (65)  

 
 
 

  (61)  

 
 
 

  SG&A  

 
 
 

  (25)  

 
 
 

  (4)  

 
 
 

  --  

 
 
 

  (27)  

 
 
 

  (56)  

 
 
 

  Other (income) expense, net  

 
 
 

  24  

 
 
 

  --  

 
 
 

  --  

 
 
 

  (1)  

 
 
 

  23  

 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  $               26  

 
 
 

  $              21  

 
 
 

  $           508  

 
 
 

  $        96  

 
 
 

  651  

 
 
 

  Tax expense on Earnings from Continuing Operations (d)  

 
 
 
 
 
 
 
 
 
 
 

  197  

 
 
 

  Earnings from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $       454  

 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $      0.25  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 

  The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations."  

 
 
 
 

  a)  

 
 

  Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention and the integration of systems, processes and business activities.  

 
 

  b)  

 
 

  Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.  

 
 

  c)  

 
 

  Other primarily relates to the impairment of an intangible asset and the net costs related to certain litigation.  

 
 

  d)  

 
 

  Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.  

 
 
 

 

 
 
                                                                                                                
 

  Abbott Laboratories and Subsidiaries  

 

  Details of Specified Items  

 

  Year Ended December 31, 2021  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

  Acquisition or Divestiture-related (a)  

 
 
 

  Restructuring and Cost Reduction Initiatives (b)  

 
 
 

  Intangible Amortization  

 
 
 

  Other (c)  

 
 
 

  Total Specifieds  

 
 

  Gross Margin  

 
 
 

  $               82  

 
 
 

  $            323  

 
 
 

  $        2,047  

 
 
 

  $        24  

 
 
 

  $     2,476  

 
 

  R&D  

 
 
 

  (15)  

 
 
 

  (7)  

 
 
 

  --  

 
 
 

  (84)  

 
 
 

  (106)  

 
 

  SG&A  

 
 
 

  (55)  

 
 
 

  (45)  

 
 
 

  --  

 
 
 

  (217)  

 
 
 

  (317)  

 
 

  Other (income) expense, net  

 
 
 

  1  

 
 
 

  1  

 
 
 

  --  

 
 
 

  23  

 
 
 

  25  

 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  $             151  

 
 
 

  $            374  

 
 
 

  $        2,047  

 
 
 

  $      302  

 
 
 

  2,874  

 
 

  Tax expense on Earnings from Continuing Operations (d)  

 
 
 
 
 
 
 
 
 
 
 

  578  

 
 

  Earnings from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $     2,296  

 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $      1.27  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 

  The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations."  

 
 
 
 

  a)  

 
 

  Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.  

 
 

  b)  

 
 

  Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the year in current and projected testing demand.  

 
 

  c)  

 
 

  Other primarily relates to the costs related to certain litigation, incremental costs to comply with MDR and IVDR Regulations for previously approved products, the acquisition of a research and development asset, the impairments of an equity investment and an intangible asset, and the gain on the disposition of an equity method investment.  

 
 

  d)  

 
 

  Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.  

 
 
 

 

 
 
                                                                                                                
 

  Abbott Laboratories and Subsidiaries  

 

  Details of Specified Items  

 

  Year Ended December 31, 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

  Acquisition or Divestiture-related (a)  

 
 
 

  Restructuring and Cost Reduction Initiatives (b)  

 
 
 

  Intangible Amortization  

 
 
 

  Other (c)  

 
 
 

  Total Specifieds  

 
 

  Gross Margin  

 
 
 

  $               84  

 
 
 

  $              80  

 
 
 

  $        2,132  

 
 
 

  $      156  

 
 
 

  $     2,452  

 
 

  R&D  

 
 
 

  (10)  

 
 
 

  (3)  

 
 
 

  --  

 
 
 

  (112)  

 
 
 

  (125)  

 
 

  SG&A  

 
 
 

  (108)  

 
 
 

  (40)  

 
 
 

  --  

 
 
 

  73  

 
 
 

  (75)  

 
 

  Other (income) expense, net  

 
 
 

  21  

 
 
 

  --  

 
 
 

  --  

 
 
 

  (109)  

 
 
 

  (88)  

 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  $             181  

 
 
 

  $            123  

 
 
 

  $        2,132  

 
 
 

  $      304  

 
 
 

  2,740  

 
 

  Tax expense on Earnings from Continuing Operations (d)  

 
 
 
 
 
 
 
 
 
 
 

  659  

 
 

  Earnings from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $     2,081  

 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $      1.16  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 

  The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations."  

 
 
 
 

  a)  

 
 

  Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities.  

 
 

  b)  

 
 

  Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.  

 
 

  c)  

 
 

  Other primarily relates to impairment charges related to certain assets and the costs to acquire R&D assets, partially offset by income from the settlement of litigation.  

 
 

  d)  

 
 

  Reflects the net tax benefit associated with the specified items, the resolution of prior years' tax positions and excess tax benefits associated with share-based compensation.  

 
 
 

 

 

 Cision View original content: https://www.prnewswire.com/news-releases/abbott-reports-strong-fourth-quarter-2021-results-issues-2022-forecast-301468554.html  

 

SOURCE Abbott

 
 

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

 
 
  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  •  
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  •  
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative
  •  

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

 

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

 

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

 

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

 

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×